
PharmaTimes March edition ponders, wrestles and wonders at the present life sciences zeitgeist – what a time to be alive! As the cover boldly suggests, we are in an era of patient autonomy and, thus, a brave new landscape in which the population expect and deserve access to medicines. Features examine shifting politics, the rise of "super employees," and ongoing innovation. Articles cover GLP-1s, difficult-to-treat cancers, top therapies of 2026, and AI's relentless advance.

The New Year edition looks forward with vim, vigour and vision! We are, after all, in the midst of transformation. In drugs, through development, across trials and amid the melting both of digital and AI. It is – at once – exciting, curious and slightly imposing. In this edition we focus on all the aforementioned themes, and NHS turbulence, predictions for 2026, healthcare comms, the future of GLP-1s, online pharmacies, radiology progress, patient centricity 2.0 and more.

The bells are ringing out for another spectacular Christmas edition of PharmaTimes. This year, we recline and reflect on a transformative year across the pharmaverse, with wistful reminiscences from our panel of industry gurus. There is also plenty to unwrap from the NHS, as we explore how pharma will be breaking bread with public health in the months ahead.

In this edition we dare to dream – fever dream, no less – about the future of the NHS. We go beyond the current chaos and speculate about the possibilities built on the founding principles, but without any of the peeling paint and dated equipment. There are also features that focus on the conditions of our times – MND, mental health and even the very skin we live in.

As an occupation at the very epicentre of healthcare, the nurse is a constant and iconic presence. In this edition of PharmaTimes, we demonstrate how this reassuring and essential presence within our industry's ecosystem continues to evolve. Talking of evolution, we will also fearlessly segway into the all-encompassing era of AI. Once a vague conversation, but now an often inspiring but slightly daunting reality, the robots are here to stay! In addition, we check out pharmacovigilance, dissect Keir Starmer, explore clinical trial data, peruse patient access and much, much more!

The new era of pharma is not just here – we are living through it. Our latest issue is about progress, getting there and arriving.

In this bold edition we talk about weight loss drugs – are they healthcare products, an NHS saviour or a complex cosmetic project? We also follow the astonishing and seemingly unstoppable acceleration of AI and the instant impact it is having on industry marketing, the use of data and humankind itself. Features on future innovation, decoding Parkinson’s disease, pharmacovigilance, the link between animal and public health, a review of our International Clinical Researcher of the Year Awards and what decisions must be made about the NHS, complete a tubthumping edition of pharma’s most intrepid periodical.

As new Pharmatimes, equidistant between the beginning and end of 2025, launches we can never be accused of ducking the Zeitgeist! Indeed, we seize weight loss drugs, NHS rebooting, AI impact, vaccine progress, clinical trials evolution and culture shaping with steely determination. It is, after all, the most transformative chapter in our industry's history...

The spectre, the shadow, the shock to the system! Yes, folks, this time we are focussing on the accumulation of humanity’s biggest dreams and worst nightmares. It’s AI time! And we’re talking about AI healthcare, AI public health, AI hospitals, AI pharma and AI patients. It’s the force of neo-nature over which we have some but not all control, and the pages of this periodical do not dodge the issues dominating our industry.

As the cover so boldly suggests, we’re talking ‘women in pharma’. Progress, ambitions, direction, understanding and essence. Indeed, this edition focuses on the dimensions of difference that only women can offer – it is about shaping new cultures through equity, the transformational possibilities of women leading and igniting clinical trials through gender distinction. Above all, we are highlighting why the future for women across life sciences must equate to proportional representation. Meanwhile, we’ve also got features on antibiotics resistance, AI assisted health outcomes, the rebuilding of UK public health and how a pub is triggering conversations about men’s health.

This edition of PharmaTimes is about the radical new look that pharma rocks these days – with it emerging dimensions, possibilities and cultures. In the spirit of this realisation, we look at the increasing role of selfcare as part of reshaping national health, while also appreciating why the laser focus of modern meds must come with adherence.

The great table of debate has been pulled up, as argument and counter argument wrestle for supremacy in the first tubthumping PharmaTimes of the year. Indeed, we stare down all the most pressing issues of 2025 including AI, modern comms, misinformation, mass screening, weight loss drugs, the future of the NHS, digital drugs and the promised land of patient inclusivity. Yep, this year – more than any other in human history






Skin deep dive. Further collaboration is needed to improve timely access to the latest innovations
Features, 31 October 2025










